INTRODUCTION
Psoriatic arthritis (PsA) has been classically defined as an inflammatory arthritis associated with psoriasis (1) . However, this definition reflects only in part the large spectrum of musculoskeletal disorders found in patients with psoriasis (2) . Thus, due to the heterogeneity of its expression, PsA may be overdiagnosised or underdiagnosised (3) . Patients with arthropathy or enthesopathy of various types, psoriasis may be overdiagnosed as PsA in presence of cutaneous.
DIAGNOSIS
In comparison with other relevant inflammatory arthropathies, such as gout, infectious arthritis, rheumatoid arthritis (RA), and reactive arthritis, all diseases in which a definite diagnosis is frequently possible only by means of laboratory investigations, in PsA true laboratory diagnostic markers are lacking. In fact, some markers are used more to differentiate other diseases than to characterise PsA. For example in polyarticular PsA, which may be in some cases indistinguishable from RA, some laboratory markers, such as rheumatoid factor (RF) or the more specific and recently introduced antibodies to cyclic citrullinated peptides (anti-CCP), may be useful to better identify RA. However, RF was found in 5% to 13% of patients with PsA (4, 5) and anti-CCP may be found in almost similar percentage (6, 7) . In a recent paper by Helliwell, reporting the results of the CASPAR study, anti-CCPs were detected in 26/588 patients with PsA (%), 15/388 (7%) with polyarticular variety and 11/200 (10%) with non-polyarticular PsA (6) . These data, showing that the occurrence of anti-CCP was not limited to the polyarthritis, confirmed those reported by another recent study by Bogliolo et al (7) . Anti-CCPs were detected in 16/102 patients (15.7%), which were mostly (68%) affected with symmetric polyarthritis, and in 2/20 (10%) with either mono-oligoarthritis. In this population, 19/102 patients have RF and anti-CCPs were present in 11 of them. Thus in PsA, the presence of anti-CCP is not restricted to those with clinical pictures resembling RA and so they seem unreliable as a marker of RA. However, as in RA, their presence is associated with an increased number of erosions, probably reflecting a more severe outcome (7). As mentioned above, the determination of ESR and/or CRP is frequently disappointing in PsA, since they are both elevated in only half of the patients with PsA (4, 5, 8) . In a multicenter study examining the characteristics of 1306 Italian patients with PsA, abnormal levels of ESR and CRP respectively occurred in 52.2% and in 52.6% of the cases (9) . Interestingly, these indices are significaly elevated in elderly onset PsA, probably reflecting more increased levels of proinflammatory cytokines in comparison with younger onset PsA and a more severe outcome (10) (11) (12) . A frequently neglected aspect, which however could be useful in suggesting the diagnosis, is the abundance of the synovial fluid (SF) effusion in patients with PsA, much higher in comparison with other arthropathies (13) . These levels reflect the high degree of vascularisation of synovial membrane in PsA, higher than in RA (14, 15) and the overexpression of angiogenic factors, such as transforming growth factor β (TGFβ) and vascular endothelial growth factor (VEGF), were found increased in the SF of PsA (16) . When available, SF analysis may offer additive information useful for the diagnosis, such as the increasing number of leukocytes, which underlines the inflammatory nature of the effusion even in a patient with normal serum levels of acute phase response.
DISEASE ACTIVITY
In PsA, when the most popular laboratory markers of inflammation, such as ESR and CRP, are within normal levels, there is no convincing alternative for the evaluation of disease activity. However, when these two markers are increased, their utility is undeniable. In particular, ESR seems the most related with clinical scores (17) . However, it is important to observe that although ESR and/or CRP are included in the most utilised response criteria for RA, such as ACR and DAS, these are also considered reliable in the assessment of PsA (8) .
PROGNOSIS
This is probably the field in which laboratory markers, including ESR and CRP, seem the most useful in PsA. Elevated levels of ESR have been proposed as one of the best predictors of damage progression (18) . Gladman et al reported that a low ESR is protective, while an ESR >15 mm/h is one of the factors associated with an increased mortality in PsA (19, 20) . Interestingly, we found that elevated IL-1β levels in SF of patients with early disease (<6 months), may be predictive of an evolution in polyarticular form at follow-up (21) . This observation is in keeping with the crucial role that inflammatory cytokines play in PsA (22) , probably related with genetic predisposition. TNF-α promoter polymorphism or a gene in linkage disequilibrium with TNF-α may also contribute to confer predisposition or increase susceptibility to psoriasis and PsA (23) . One study looking at the TNFβ+252 and TNFα-308 polymorphisms did not find any differences in allele frequencies between PsA patients and matched controls, however both polymorphisms were significantly associated with the presence of joint erosions and the progression of joint erosions in early PsA (24) . The genetic predisposition has been also investigated by HLA typing. The most involved allele for psoriasis is HLA-CW6, which is also recently known as PSORSI, especially in addition to alleles in linkage disequilibrium HLA B13 and B17 (B57) and the class II allele, HLA DR7 (25) (26) (27) (28) . The presence of HLA-CW*0602 is associated with more severe and early onset psoriasis (29) and was found in 100% of patients with guttate psoriasis (30) . In PsA, the most frequent associations are HLA-B38 and HLA-B39, both splits of HLA-B16, in peripheral disease and HLA-B27 in axial disease (27, 28) . Some propose that HLA-DR7 is associated with a more severe outcome and HLA-DR4 to more frequent erosions, but these data need confirmation (31) .
EVALUATION OF DRUG THERAPY
Laboratory investigations are among the most useful tools to control the influence of drugs, both therapeutic and side effects. Obviously, in the patients having basal high values of ESR and CRP, their reduction was generally interpreted as satisfactory because they were usually associated with the improvement of other response criteria of disease activity. The recent introduction in PsA of anti-TNF-α agents, soon after their demonstration of remarkable efficacy in treating DMARDrefractory RA, has stimulated the research also in the field of the possible laboratory markers. To this purpose several substances have been proposed, but without a definite demonstration of their utility. TNF-α blockers have demonstrated to be useful in the management of many clinical disease expressions including peripheral arthropathy, axial involvement, enthesopathy and skin manifestations (32, 33) . Furthermore, they are able to slow down the disease progression, as proven radiologically. Recommendations or guidelines for the anti-TNF use in PsA, carefully consider the heterogeneity of clinical presentations and include ESR and CRP as a marker of disease activity (34, 35) . However, the observation found in ankylosing spondylitis does not seem to be confirmed in PsA, that patients with elevated CRP or ESR tend to respond better to TNF inhibitor therapy (36) .
